Sanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera Forbion moves into late-stage investing with $210M fund Can Biogen rebound in ALS? Maybe so, new antisense drug data suggest Sponsored: Keep post-pandemic trials on track: how the right clinical supply chain partner helps sponsors avoid trial disruption, now and going forward Bayer's heart failure pill hinders kidney disease, heart disease in phase 3 Tranquis debuts with $30M for immune cell approach to neurodegenerative diseases FDA clears Nonin's hand-held carbon monoxide poisoning meter for first responders Preventing breast cancer metastasis by reactivating natural killer immune cells Takeda teams up with Twist Bioscience to boost biologics R&D Featured Story | By Ben Adams While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera Therapeutics. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Forbion has expanded into late-stage biotech investing by holding the first close of a planned €250 million ($284 million) fund. The growth fund, which received money from Eil Lilly, will work with a who’s who of European biotech leaders to execute its investment strategy. read more By Amirah Al Idrus It’s no secret: Amyotrophic lateral sclerosis is a tough nut to crack. And no one knows that better than Biogen, which in 2013 saw its last ALS effort go up in flames in phase 3. Now, it’s unveiling full phase 1/2 data for a prospect that emerged from this shift: tofersen, an antisense oligonucleotide licensed from Ionis. read more Monday, July 6, 2020 Facing a new reality, pharma and biotech companies must address ongoing clinical trial distribution challenges. Here's how a supply chain partner can help keep your post-pandemic clinical program on track. read more By Amirah Al Idrus Five years after kicking off a massive phase 3 program, Bayer has good news for its heart failure pill finerenone. The drug beat placebo at staving off progression of kidney disease and lowered the risk of heart attacks and strokes in patients with chronic kidney disease and Type 2 diabetes. read more By Amirah Al Idrus Nerve cell inflammation has long been linked to neurodegenerative disease, but as a byproduct rather than a cause. Over the years, scientists have debunked that theory, and, now, Tranquis Therapeutics is launching with $30 million to create a new class of medicines for illnesses like amyotrophic lateral sclerosis and Alzheimer’s disease. read more By Conor Hale The pulse oximeter manufacturer Nonin Medical received a new FDA clearance for a hand-held vital sign monitor designed to help emergency first responders and firefighters immediately assess patients suffering from a heart attack or physical injury, as well as those affected by carbon monoxide poisoning and smoke inhalation. read more By Angus Liu Scientists at Johns Hopkins University discovered that breast cancer cells can alter the function of natural killer cells to promote metastasis. Pairing FDA-approved DNMT inhibitors with receptor-blocking antibodies could prevent this reprogramming and stop breast cancer from spreading, they showed. read more By Ben Adams Japanese Big Pharma Takeda has paired with synthetic DNA services company Twist Bioscience to level up its biologics capacity. read more Resources Sponsored by: Cytiva On-demand video: fuel gene therapy development and production with modern AAV workflows. Sponsored by: LexisNexis Risk Solutions With today’s rapidly evolving environment, we have created this five-part content series to highlight pressing issues and topics that are more pertinent today than ever before. Sponsored by: Cambrex The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities, and employees than ever before, our experts have contributed more articles to our biggest eBook yet. Sponsored by: EVERSANA How predictive analytics and machine learning have the potential to transform healthcare by predicting “Patient Switching Behaviors.” Sponsored by: Recro Gainesville Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project. Sponsored by: PRA Health Sciences Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need. Sponsored by: Systech Get an inside look… Merck shares its next-generation approach to supply chain protection with new digital platforms, including Blockchain. Sponsored by: Automation Anywhere Built on advances in Artificial Intelligence (AI), data mining, and information integration into various systems at 100% accuracy, the new era of intelligent automation is integral to life sciences for devising new treatments faster and at a lower expense. Sponsored by: Research Solutions Learn four ways to squeeze more value from your limited R&D resources. Sponsored by: BioAnalytix Download this eBook and Learn the Advanced Analytical Approaches for Improved Development of Cell and Gene Therapies Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 